Overview
- The 76-week SYNCHRONIZE-1 study in adults with overweight or obesity without type 2 diabetes showed 16.6% average weight loss on survodutide versus 3.2% with placebo.
- A total of 85.1% of people on the drug lost at least 5% of body weight, and most of the loss came from fat with larger drops in waist size than placebo.
- Gastrointestinal problems were common and mostly mild to moderate, occurring more often during the dose-escalation period, and no new safety issues were reported.
- The drug activates both GLP-1 and glucagon receptors, and Boehringer, which licensed rights from Zealand Pharma, is advancing it as a potential rival to Novo Nordisk and Eli Lilly offerings.
- Full SYNCHRONIZE-1 data are planned for the American Diabetes Association meeting in June, with additional program readouts expected later in 2026.